title: Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
abstract: Experimental immunoglobulin preparations for treatment of group B streptococcal (GBS) infections contain low levels of functional antibody and exhibit lot-to-lot variability. GBS capsular polysaccharide-protein conjugate vaccines have recently been shown to produce high serum levels of type-specific antibody in healthy volunteers. Treatment of neonatal mice 4 h after inoculation with an ordinarily lethal dose of GBS type Ia, Ib, or III with pooled human serum from adults who had received GBS type Ia capsular polysaccharide-tetanus toxoid vaccine (Ia CPS-TT), Ib CPS-TT, or III CPS-TT resulted in 63%, 70%, and 75% survival, respectively. In contrast, < or = 17% of the infected mice treated with normal human serum or saline survived. These results demonstrate the therapeutic activity of GBS polysaccharide conjugate vaccine-induced antiserum and provide a rationale for the use of these vaccines in producing a functional, high-titered intravenous immunoglobulin preparation for clinical use.
authors.affiliation: Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Paoletti
authors.forename: J
authors.initials: J
authors.lastname: Pinel
authors.forename: A K
authors.initials: AK
authors.lastname: Rodewald
authors.forename: D L
authors.initials: DL
authors.lastname: Kasper
mesh_terms: D000328:Adult; D000818:Animals; D000831:Animals, Newborn; D000917:Antibody Formation; D016667:Bacterial Capsules; D001428:Bacterial Vaccines; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D013290:Streptococcal Infections / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D022541:Streptococcal Vaccines; D013292:Streptococcus agalactiae / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology; D014614:Vaccines, Synthetic
chemical_list: D001428:Bacterial Vaccines; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides; D022541:Streptococcal Vaccines; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic; C105866:group B streptococcal type III capsular polysaccharide-tetanus toxoid vaccine; C105864:group B streptococcal type Ia capsular polysaccharide-tetanus toxoid vaccine; C105865:group B streptococcal type Ib capsular polysaccharide-tetanus toxoid vaccine